Keele Research Repository

Article

Curley, P, Giardiello, M, Liptrott, NJ, Dickens, D, Moss, DM, Hobson, J, Savage, AC, McDonald, T, Siccardi, M, Rannard, S and Owen, A (2017) In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line. Journal of Interdisciplinary Nanomedicine, 2 (3). pp. 157-169.

Curley, P, Rajoli, RK, Moss, DM, Liptrott, NJ, Letendre, S, Owen, A and Siccardi, M (2016) Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation. Antimicrobial Agents and Chemotherapy, 61 (1).

Giardiello, M, Liptrott, NJ, McDonald, T, Moss, DM, Siccardi, M, Martin, P, Smith, D, Gurjar, R, Rannard, S and Owen, A (2016) Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. Nature Communications, 7.

Moss, DM, Liptrott, NJ, Siccardi, M and Owen, A (2015) Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. Frontiers in Pharmacology, 6.

Moss, DM, Liptrott, NJ, Curley, P, Siccardi, M, Back, DJ and Owen, A (2013) Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro. Antimicrobial Agents and Chemotherapy, 57 (11). pp. 5612-5618.

Moss, DM, Kwan, WS, Liptrott, NJ, Smith, DL, Siccardi, M, Khoo, SH, Back, DJ and Owen, A (2011) Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir. Antimicrobial Agents and Chemotherapy, 55 (2). pp. 879-887.